One Indiana addiction specialist doesn ’ t shy away from telemedicine, but he still requires in-person visits to begin and maintain his patients ’ Suboxone prescriptions.Kaiser Health News (Source: Medscape Medical News Headlines)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.

{ 0 comments }

WASHINGTON (AP) — U.S. health officials on Thursday approved the first injectable form of the leading medication to treat patients recovering from addiction to heroin, prescription painkillers and other opioids.
The Food and Drug Administration approved once-a-month Sublocade for adults with opioid use disorder who are already stabilized on addiction medication.
The monthly injection has the potential to reduce dangerous relapses that occur when patients stop taking the currently available daily medication. But that benefit has not yet been shown in studies and the new drug comes with a hefty price: $1,580 per monthly dose. The older version of the drug, Suboxone, costs $100 a month
The approval comes amid the deadliest drug epidemic in U.S. history and a longstanding gap in medication-b…

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.

{ 0 comments }

Orexo nabs regulatory win for fast-dissolving opioid dependence therapy

November 21, 2017

Orexo (STO:ORX) said today that the European Medicines Agency granted marketing authorization for its Zubsolv rapidly-disintegrating treatment for opioid dependence. The buprenorphine and naloxone sublingual tablet is the first to be approved in Europe with six different strengths, according to the Sweden-based company. Get the full story at our sister site, Drug Delivery Business News. The post […]

Read the full article →

Long- and Short-Acting Opioid Addiction Meds Equally Effective Long- and Short-Acting Opioid Addiction Meds Equally Effective

November 17, 2017

Extended-release naltrexone and buprenorphine/naloxone are similarly efficacious in preventing relapse for patients with opioid use disorder, although naltrexone was more difficult to initiate.Medscape Medical News (Source: Medscape Medical News Headlines) MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.

Read the full article →

Pediatricians ’ Counseling Hopes To End Teen Opioid Addiction Before It Starts

November 16, 2017

WAREHAM (CBS) – One out of every four teenagers admits to misusing or abusing, a prescription drug. It’s a dangerous road that can lead to addiction. To prevent and treat drug-use in kids there is now a first-of-its-kind program tackling the issue head-on right at the pediatrician’s office. At Wareham Pediatrics, the Cat in the […]

Read the full article →

Opioid treatment drugs have similar outcomes once patients initiate treatment

November 16, 2017

NIDA study compares buprenorphine/naloxone combination to extended release naltrexone. (Source: National Institutes of Health (NIH) News Releases)

Read the full article →

Study: Head-to-head comparison of opioid use disorder therapies finds similarities

November 16, 2017

A study published today in The Lancet found that two different therapies used to treat opioid use disorder – an extended-release naltrexone injection and a combination of buprenorphine and naloxone – have similar outcomes once patients get past the hurdle of starting treatment. This is the first study to compare the combination therapy and naltrexone head-to-head in […]

Read the full article →

Opioid Addiction Treatments Face Off in US Trial

November 16, 2017

CHICAGO (AP) — The first U.S. study to compare two treatments for opioid addiction finds a monthly shot works as well as a daily drug to prevent relapse. The shot requires days of detox first and that proved to be a stumbling block for many. For those who made it past that hurdle, the shot […]

Read the full article →

Extended-Release Naltrexone Seems as Effective as Standard Treatment for Opioid Dependence (FREE)

October 20, 2017

By Amy Orciari Herman Edited by Susan Sadoughi, MD Injectable extended-release naltrexone (Vivitrol) appears to be as safe and effective as daily oral buprenorphine-naloxone for treating opioid dependence, according to a Norway-based, noninferiority trial … (Source: Physician’s First Watch current issue)

Read the full article →

Opioid Blocker as Good as Suboxone in First Head-to-Head Trial (CME/CE)

October 20, 2017

(MedPage Today) — Monthly naltrexone (Vivitrol) non-inferior to buprenorphine/naloxone (Source: MedPage Today Pain Management) MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.

Read the full article →